140 related articles for article (PubMed ID: 30480878)
1. Platelet miR-28 expression level and thrombocytosis in MPN patients.
Stolyar MA; Gorbenko AS; Olkhovskiy IA
Int J Lab Hematol; 2019 Apr; 41(2):e43-e45. PubMed ID: 30480878
[No Abstract] [Full Text] [Related]
2. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of myeloproliferative neoplasms.
Skoda RC; Duek A; Grisouard J
Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
[No Abstract] [Full Text] [Related]
5. Focus on the epigenome in the myeloproliferative neoplasms.
Kim E; Abdel-Wahab O
Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
[TBL] [Abstract][Full Text] [Related]
6. The transcription factor NFE2 enhances expression of the hematopoietic master regulators SCL/TAL1 and GATA2.
Siegwart LC; Schwemmers S; Wehrle J; Koellerer C; Seeger T; Gründer A; Pahl HL
Exp Hematol; 2020 Jul; 87():42-47.e1. PubMed ID: 32593672
[TBL] [Abstract][Full Text] [Related]
7. ZBTB44-FLT3 fusion in a patient with a myeloproliferative neoplasm.
Zhou X; Yang C; Zou Z; Lang X; Chen P; Chen S; Wang K; Chen Y; Hao Y; Chen N; Ding J; Li Y; Shen Y; Xiao S
Br J Haematol; 2020 Oct; 191(2):297-301. PubMed ID: 32866288
[No Abstract] [Full Text] [Related]
8. Platelet phospholipids in thrombocytosis due to myeloproliferative disorders.
Breuer JH; Harsányi V; Solti V; Hollán SR
Haemostasis; 1981; 10(3):134-40. PubMed ID: 7262643
[TBL] [Abstract][Full Text] [Related]
9. Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm.
Hu AY; Zhou T
Br J Haematol; 2019 Jan; 184(1):8. PubMed ID: 30407632
[No Abstract] [Full Text] [Related]
10. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).
Visconte V; Tabarroki A; Zhang L; Hasrouni E; Gerace C; Frum R; Ai J; Advani AS; Duong HK; Kalaycio M; Saunthararajah Y; Sekeres MA; His ED; Shetty S; Rogers HJ; Tiu RV
Am J Hematol; 2014 Aug; 89(8):862. PubMed ID: 24796269
[No Abstract] [Full Text] [Related]
11. Impact of Notch disruption on myeloid development.
Francis OL; Chaudhry KK; Lamprecht T; Klco JM
Blood Cancer J; 2017 Aug; 7(8):e598. PubMed ID: 28841212
[No Abstract] [Full Text] [Related]
12. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
13. Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis.
Clezardin P; McGregor JL; Dechavanne M; Clemetson KJ
Br J Haematol; 1985 Jun; 60(2):331-44. PubMed ID: 4005182
[TBL] [Abstract][Full Text] [Related]
14. Micronuclei, dmin chromosomes and MYC amplifications as a singular presentation of myeloid malignancies.
Montoro MJ; Rivero E; Teixidó M; Rodriguez Y; Chávez C; Salamero O; Navarrete M; Talavera E; Ortega M; Valcárcel D
Br J Haematol; 2020 Oct; 191(1):e19-e22. PubMed ID: 32627175
[No Abstract] [Full Text] [Related]
15. Preliminary investigation about the expression of tubulin in platelets from patients with iron deficiency anemia and thrombocytosis.
Yung KC; Zhang ZW; Yu WJ; Qiu JF; Xu CW; He CL; Xu XR; Yin J
Hematology; 2018 Sep; 23(8):549-557. PubMed ID: 29499633
[TBL] [Abstract][Full Text] [Related]
16. Mutant calreticulin: when a chaperone becomes intrusive.
Cazzola M
Blood; 2016 Mar; 127(10):1219-21. PubMed ID: 26965919
[TBL] [Abstract][Full Text] [Related]
17. Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.
Čokić VP; Mossuz P; Han J; Socoro N; Beleslin-Čokić BB; Mitrović O; Subotički T; Diklić M; Leković D; Gotić M; Puri RK; Noguchi CT; Schechter AN
PLoS One; 2015; 10(8):e0135463. PubMed ID: 26275051
[TBL] [Abstract][Full Text] [Related]
18. Normal and malignant megakaryopoiesis.
Wen Q; Goldenson B; Crispino JD
Expert Rev Mol Med; 2011 Oct; 13():e32. PubMed ID: 22018018
[TBL] [Abstract][Full Text] [Related]
19. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
20. ZBTB7A links tumor metabolism to myeloid differentiation.
Redondo Monte E; Kerbs P; Greif PA
Exp Hematol; 2020 Jul; 87():20-24.e1. PubMed ID: 32525064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
